Enzyvant Announces Merger with Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonologyCARY, N.C.,...
Antimicrobial
Merakris Announces Review in Biomedicines Medical Journal Highlighting Therapeutic Potential of Cell-Free Amniotic Fluid
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines...
Kane Biotech Announces Third Quarter 2022 Financial Results
Company Files First 510(k) Application in Wound CareWINNIPEG, Manitoba, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE;...
Rio Tinto donates $500,000 to the MUHC Foundation to fight antimicrobial resistance
The gift will create the Antimicrobial Resistance Discovery Incubator, which will fund innovative new projects to prevent and treat drug...
BioLife Sciences Inc. (OTC:PK BLFE) is Pleased to Announce Its Q1 2023 Slated Release of Its Copper-Infused Fabric Pot Prototype
HENDERSON NV, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – MFusion infuses copper metal ions directly into every sub-bundle...
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation...
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1...
Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection
Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a...
BioLife Sciences Inc. Seeks to Retain an Auditing and Consulting Services Firm
HENDERSON, NV, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences Inc. (“BioLife” or the “Company”) (OTCPK: BLFE)...
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule
LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection...
UCSF QBI Congratulates Nevan Krogan, Ph.D., as a Recipient of Prestigious French Legion of Honor Award and Welcomes New, Comprehensive Relationship with Institut Pasteur
– Two Academic Powerhouses form Institut Pasteur-UCSF QBI Center of Excellence in Emerging Diseases with Planned Operations/Locations in San Francisco...
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in...
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole...
DEINOVE – Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address...
Spero Therapeutics to Present Data at IDWeek 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,...
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung DiseaseMENLO PARK, Calif., Oct. 19, 2022...
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
Studies demonstrate that T2Bacteria and T2Candida panels enable sensitive and specific diagnosis to enhance the standard of careLEXINGTON, Mass., Oct....
Kane Biotech to Present at Symposium on Advanced Wound Care Fall Forum
Company presenting technologies for improving patient outcomes in wound careWINNIPEG, Manitoba, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc....
